Capricor Therapeutics (NASDAQ:CAPR) Stock Price Up 6%

Capricor Therapeutics Inc (NASDAQ:CAPR) shares rose 6% on Thursday . The stock traded as high as $5.59 and last traded at $5.29, approximately 1,772,155 shares were traded during mid-day trading. A decline of 55% from the average daily volume of 3,930,246 shares. The stock had previously closed at $4.99.

CAPR has been the topic of several analyst reports. HC Wainwright reaffirmed a “buy” rating and issued a $9.00 target price on shares of Capricor Therapeutics in a report on Thursday, March 19th. Zacks Investment Research lowered shares of Capricor Therapeutics from a “strong-buy” rating to a “hold” rating in a report on Tuesday, March 24th. ValuEngine lowered shares of Capricor Therapeutics from a “buy” rating to a “hold” rating in a report on Thursday, April 30th. Finally, Maxim Group assumed coverage on shares of Capricor Therapeutics in a report on Saturday, May 16th. They set a “buy” rating and a $12.00 price objective on the stock.

The business’s fifty day simple moving average is $3.89 and its 200 day simple moving average is $2.09.

Capricor Therapeutics (NASDAQ:CAPR) last issued its quarterly earnings data on Thursday, May 14th. The biotechnology company reported ($0.30) EPS for the quarter, topping analysts’ consensus estimates of ($0.33) by $0.03. Capricor Therapeutics had a negative net margin of 750.83% and a negative return on equity of 128.89%. The firm had revenue of $0.19 million for the quarter, compared to analyst estimates of $0.21 million. As a group, equities analysts anticipate that Capricor Therapeutics Inc will post -1.46 earnings per share for the current year.

A hedge fund recently bought a new stake in Capricor Therapeutics stock. Jane Street Group LLC bought a new stake in shares of Capricor Therapeutics Inc (NASDAQ:CAPR) during the first quarter, according to its most recent 13F filing with the SEC. The institutional investor bought 24,150 shares of the biotechnology company’s stock, valued at approximately $29,000. Jane Street Group LLC owned 0.19% of Capricor Therapeutics at the end of the most recent quarter. 1.74% of the stock is owned by institutional investors.

About Capricor Therapeutics (NASDAQ:CAPR)

Capricor Therapeutics, Inc (NASDAQ:CAPR) is a clinical-stage biotechnology company focused on the discovery, development and commercialization of first-in-class biological therapeutics for the treatment of rare disorders. Capricor’s lead candidate, CAP-1002, is an allogeneic cell therapy that is currently in clinical development for the treatment of Duchenne muscular dystrophy.

Read More: Example of operating income, EBIT and EBITDA

Receive News & Ratings for Capricor Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Capricor Therapeutics and related companies with's FREE daily email newsletter.